Go Pro
→ BofA: Digital Dollar Coming 2025-2030 (From Decentralized Masters) (Ad)tc pixel Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$17.23 +0.41 (+2.46%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$17.17 -0.06 (-0.37%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold
Based on 4 Analyst Ratings
Sell
1
Hold
1
Buy
2

Based on 4 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 1 has given a sell rating, 1 has given a hold rating, and 2 have given a buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
7/26/25 to 7/26/26		1 Month Ago
6/26/25 to 6/26/26		3 Months Ago
4/27/25 to 4/27/26		1 Year Ago
7/26/24 to 7/26/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldModerate BuyModerate BuyBuy

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalMedical CompaniesBroader Market
Consensus Rating Score
2.25
2.29
2.52
Consensus RatingHoldHoldModerate Buy
Predicted UpsideN/A974.40% Upside14.30% Upside
News Sentiment Rating
Neutral News

See Recent TAK News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
6/29/2026
Zacks Research logo
Zacks Research
Not Rated
 DowngradeHold ➝ Strong Sell
6/23/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 DowngradeHold (C) ➝ Hold (C-)
4/8/2026
Sanford C. Bernstein logo
Sanford C. Bernstein
3 of 5 stars
 UpgradeMarket Perform ➝ Outperform
1/13/2026
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:33 AM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 21, 2026. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • The company reported a solid earnings per share of $0.56 in its latest quarterly results, indicating strong profitability.
  • With a return on equity of 11.20%, Takeda Pharmaceutical Company Limited demonstrates effective management of shareholder equity, which can be attractive to investors.
  • The firm generated revenue of approximately $6.90 billion during the last quarter, showcasing its robust market presence and operational scale.
  • Recent institutional investments have increased significantly, with hedge funds boosting their stakes, suggesting growing confidence in the company's future performance.
  • The current stock price is around $15, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The company has a net margin of only 4.31%, which may indicate challenges in maintaining profitability compared to competitors.
  • Analysts forecast a modest earnings per share of 1.12 for the current year, suggesting limited growth potential in the near term.
  • With 9.17% of the stock owned by hedge funds and institutional investors, there may be less room for retail investors to influence stock performance.
  • Recent market volatility in the biopharmaceutical sector could pose risks to stock stability and investor returns.
  • Takeda Pharmaceutical Company Limited operates in a highly competitive industry, which may impact its ability to sustain market share and profitability.

TAK Forecast - Frequently Asked Questions

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There is currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TAK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 2 downgrades by analysts.

Takeda Pharmaceutical has been rated by research analysts at Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Takeda Pharmaceutical less than other "medical" companies. The consensus rating score for Takeda Pharmaceutical is 2.25 while the average consensus rating score for "medical" companies is 2.29. Learn more on how TAK compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Takeda Pharmaceutical Recommendations


This page (NYSE:TAK) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Once you see it, you can't unsee it
Central banks are hoarding gold at the strongest pace since 1967, even as stocks sit near record highs. Bank C...
Behind the Markets | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
Have you seen Elon’s new “supercurrency”? (It affects you)
Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...
StocksToTrade | Sponsoredtc pixel